Ho et al. found that upadacitinib may impede the progression of bone erosion in patients with RA. Additionally, bone scans of patients with limited exposure to conventional synthetic disease-modifying antirheumatic drugs showed bone erosion regression, which may result from upadacitinib’s inhibition of Janus kinase 1.
![](https://www.the-rheumatologist.org/wp-content/uploads/2016/10/dreamstime_BoneJoint_500x270-150x150.jpg)